Disease · MONDO_0007648
hereditary diffuse gastric adenocarcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hereditary diffuse gastric adenocarcinoma. Diseases, record MONDO_0007648. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007648
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- FDGC, HDGC, familial diffuse cancer of stomach, familial diffuse gastric cancer, hereditary diffuse cancer of stomach, hereditary diffuse gastric cancer
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVOCERANIB | CHEMBL3186534 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CRIZOTINIB | CHEMBL601719 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FULVESTRANT | CHEMBL1358 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SINTILIMAB | CHEMBL4297829 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ALK | ALK tyrosine kinase receptor | 1 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/238 | Drugs and targets |
| EML4 | EML4-ALK | 1 | EML4-ALK inhibitor | Phase 2 | https://conductscience.org/library/genes/27436 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha antagonist; Estrogen receptor degrader | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor 2 | 1 | Vascular endothelial growth factor receptor 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| MET | Hepatocyte growth factor receptor | 1 | Hepatocyte growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/4233 | Drugs and targets |
| MST1R | Macrophage-stimulating protein receptor | 1 | Macrophage-stimulating protein receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/4486 | Drugs and targets |
| NPM1 | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1 | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/4869 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 antagonist | Phase 1/2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| ROS1 | Proto-oncogene tyrosine-protein kinase ROS | 1 | Proto-oncogene tyrosine-protein kinase ROS inhibitor | Phase 2 | https://conductscience.org/library/genes/6098 | Drugs and targets |
| TYMS | Thymidylate synthase | 1 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours | Phase 2 | 33 | 2025-10-30 | Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation | CRIZOTINIB, FULVESTRANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03355612 | XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma | Phase 3 | 456 | Gastric Carcinoma | CAPECITABINE, OXALIPLATIN, RIVOCERANIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07025889 | IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer | Phase 1/2 | 55 | Gastric Cancer | SINTILIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | 6 of 6 | 27 of 27 | 33 | NCT03620643 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: deaths from any cause | 6 of 6 | 20 of 27 | 33 | NCT03620643 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: serious adverse events | 4 of 6 | 5 of 27 | 33 | NCT03620643 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 35119530 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007648
GET https://conductscience.org/api/diseases/v1/MONDO_0007648/drugs